Phaseline

Companies › Binhui Biopharmaceutical

Binhui Biopharmaceutical: clinical trials, targets and expected readouts

3 active drug programs in 8 registered trials: 7 Phase 1, 1 Phase 3; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OH2 Injection
Oncolytic type 2 herpes simplex virus
–Phase 3Melanoma; Advanced Liver Cancer; Solid TumorMar 2027
OH2
Oncolytic Type 2 Herpes Simplex Virus expressing GM-CSF
–Phase 1Solid TumorDec 2027
Pucotenlimab (HX008)
Programmed cell death protein 1 inhibitor
PDCD1Phase 1Solid Tumor; Melanoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05698459OH2 InjectionPhase 1Advanced Liver CancerOncologyAug 2025
NCT03866525OH2Phase 1Solid TumorOncologyAug 2025
NCT03866525Pucotenlimab (HX008)Phase 1Solid TumorOncologyAug 2025
NCT04616443OH2 InjectionPhase 1MelanomaOncologyNov 2025
NCT04616443Pucotenlimab (HX008)Phase 1MelanomaOncologyNov 2025
NCT05868707OH2 InjectionPhase 3MelanomaOncologyMar 2027
NCT07382531OH2 InjectionPhase 1Solid TumorOncologyDec 2027
NCT07382531OH2Phase 1Solid TumorOncologyDec 2027

Targets

PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Companies built like this

Shanghai Juncell Therapeutics Guangzhou Gloria Biosciences CrystalGenomics Immorna Biotherapeutics Orca Biosystems

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.